Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: Federal Circuit
Ignorance is Bliss – for Teva
I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading
USPTO TRIPs over Myriad-Mayo guidance
Timothy W. Roberts, Chartered Patent Attorney; MA (Oxon); LL.D (honoris causa, Sheffield University) Paul G. Cole, Chartered Patent Attorney; MA (Oxon); LLM, NottinghamTrent; Visiting Professor, Bournemouth University The above UK-based European Practitioners have today filed comments at the USPTO arguing … Continue reading
Myriad Guidance Comments
The USPTO is now publishing comments http://www.uspto.gov/patents/law/comments/myriad-mayo_guidance_comments.jsp
Posted in Patent Eligible Subject Matter
Tagged biotechnology law, Federal Circuit, intellectual property, ip, Mayo, Myriad, USPTO, Warren Woessner
1 Comment
Abbvie V. Janssen Biotech –Written Description Requirement Road Map
The recent decision in Abbvie Deutschland v. Janssen Biotech and Centorcor Biologics, App. No. 2013-1338, -1346 (Fed. Cir. , July 1, 2014) deserves more attention than it has received. (A copy of the decision is available at the end of … Continue reading